McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., . . . Dallaire, B. K. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. Journal of clinical oncology, 16(8), . https://doi.org/10.1200/JCO.1998.16.8.2825
Chicago-Zitierstil (17. Ausg.)McLaughlin, Peter, et al. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-dose Treatment Program." Journal of Clinical Oncology 16, no. 8 (1998). https://doi.org/10.1200/JCO.1998.16.8.2825.
MLA-Zitierstil (9. Ausg.)McLaughlin, Peter, et al. "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-dose Treatment Program." Journal of Clinical Oncology, vol. 16, no. 8, 1998, https://doi.org/10.1200/JCO.1998.16.8.2825.